美国监管机构已正式批准基于Darzalex Faspro®的四药联合治疗方案,适用于新确诊且不适合进行干细胞移植的多发性骨髓瘤患者。这一决定为特定患者群体提供了新的治疗选择。
美国监管机构已正式批准基于Darzalex Faspro®的四药联合治疗方案,适用于新确诊且不适合进行干细胞移植的多发性骨髓瘤患者。这一决定为特定患者群体提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.